RxDoctor Payments Data

Stacy Conville, MD

Family Medicine · Ruston, LANPI 1497702880

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 112 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$596
  • Amgen$207
  • AbbVie$195
  • Ironshore Pharmaceuticals Inc.$165
  • Lilly USA, LLC$158
  • Merck$114
  • plus $683 from 18 others

What the payments were for

  • Food & beverage$2,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$12,805
Medicare patients
13
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol18$14,881
MounjaroTirzepatide14$14,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,138
OzempicSemaglutide11$10,480
Rosuvastatin Calcium15$201
Levothyroxine Sodium27$161
Nifedipine ErNifedipine15$150
Potassium Chloride17$147
Atorvastatin Calcium28$137
Losartan Potassium19$134
Omeprazole15$113
Fluticasone Propionate14$110
Amlodipine Besylate12$101
Alendronate Sodium16$97
Gabapentin12$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$98$14,88118 claims
Lilly USA, LLCMounjaro$158$14,50014 claims
GSKTrelegy Ellipta$596$14,13814 claims
Novo NordiskOzempic$97$10,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →